Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

217 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.
Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, Puu M, Yusuf S, Pfeffer MA; CHARM Investigators. Olsson LG, et al. Among authors: ducharme a. J Am Coll Cardiol. 2006 May 16;47(10):1997-2004. doi: 10.1016/j.jacc.2006.01.060. Epub 2006 Apr 27. J Am Coll Cardiol. 2006. PMID: 16697316 Free article. Clinical Trial.
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program.
Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJ, Olsson L, Rouleau JL, Young JB, Yusuf S. Ducharme A, et al. Am Heart J. 2006 May;151(5):985-91. doi: 10.1016/j.ahj.2005.06.036. Am Heart J. 2006. PMID: 16644318
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJ, Olsson L, Rouleau JL, Young JB, Olofsson B, Puu M, Yusuf S; CHARM Investigators. Ducharme A, et al. Am Heart J. 2006 Jul;152(1):86-92. Am Heart J. 2006. PMID: 16838426
Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy.
Mitchell GF, Dunlap ME, Warnica W, Ducharme A, Arnold JM, Tardif JC, Solomon SD, Domanski MJ, Jablonski KA, Rice MM, Pfeffer MA; Prevention of Events With Angiotensin-Converting Enzyme Inhibition Investigators. Mitchell GF, et al. Among authors: ducharme a. Hypertension. 2007 Jun;49(6):1271-7. doi: 10.1161/HYPERTENSIONAHA.106.085738. Epub 2007 Apr 23. Hypertension. 2007. PMID: 17452505 Free PMC article. Clinical Trial.
Temporal variations in hematocrit values in patients with left ventricular dysfunction: Relationship with cause-specific mortality and morbidity and optimal monitoring--further insights from SOLVD.
de Denus S, Tardif JC, White M, Bourassa MG, Racine N, Levesque S, Ducharme A. de Denus S, et al. Among authors: ducharme a. Can J Cardiol. 2008 Jan;24(1):45-8. doi: 10.1016/s0828-282x(08)70547-6. Can J Cardiol. 2008. PMID: 18209768 Free PMC article. Clinical Trial.
Growth Differentiation Factor-15 as a Predictor of Functional Capacity, Frailty, and Ventricular Dysfunction in Patients With Aortic Stenosis and Preserved Left Ventricular Ejection Fraction.
Basmadjian L, Bouabdallaoui N, Simard F, O'Meara E, Ducharme A, Rouleau JL, Racine N, White M, Sirois MG, Asgar A, Ibrahim R, Dorval JF, Bonan R, Cartier R, Forcillo J, El-Hamamsy I, Henri C. Basmadjian L, et al. Among authors: ducharme a. Am J Cardiol. 2023 Jan 1;186:11-16. doi: 10.1016/j.amjcard.2022.09.029. Epub 2022 Nov 3. Am J Cardiol. 2023. PMID: 36334433
Implantable Hemodynamic Monitors Improve Survival in Patients With Heart Failure and Reduced Ejection Fraction.
Lindenfeld J, Costanzo MR, Zile MR, Ducharme A, Troughton R, Maisel A, Mehra MR, Paul S, Sears SF, Smart F, Johnson N, Henderson J, Adamson PB, Desai AS, Abraham WT; GUIDE-HF, CHAMPION, and LAPTOP-HF Investigators. Lindenfeld J, et al. Among authors: ducharme a. J Am Coll Cardiol. 2024 Feb 13;83(6):682-694. doi: 10.1016/j.jacc.2023.11.030. J Am Coll Cardiol. 2024. PMID: 38325994
Effects of cold exposure on submaximal exercise performance and adrenergic activation in patients with congestive heart failure and the effects of beta-adrenergic blockade (carvedilol or metoprolol).
Blanchet M, Ducharme A, Racine N, Rouleau JL, Tardif JC, Juneau M, Marquis J, Larivée L, Nigam A, Fortier A, White M. Blanchet M, et al. Among authors: ducharme a. Am J Cardiol. 2003 Sep 1;92(5):548-53. doi: 10.1016/s0002-9149(03)00723-9. Am J Cardiol. 2003. PMID: 12943875 Clinical Trial.
217 results